Furthermore, a clinical trial with eculizumab, a long-acting human monoclonal antibody targeting C5 to block its cleavage to C5a and C5b, has shown positive results in phase 1 clinical trials of pregnant women with early-onset HELLP syndrome (440). Here, C5 is linked to HELLP syndrome.